Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass.

BACKGROUND Activation of complement during revascularization of ischemic myocardium accentuates myocardial dysfunction. Soluble human complement receptor type 1 (sCR1) is a potent inhibitor of complement, as are heparin-bonded (HB) cardiopulmonary bypass (CPB) circuits. This study sought to determine whether total complement inhibition with the combination of sCR1 and HB-CPB limits damage during the revascularization of ischemic myocardium. METHODS AND RESULTS In 40 pigs, the second and third diagonal coronary arteries were occluded for 90 minutes, followed by 45 minutes of cardioplegic arrest and 180 minutes of reperfusion. In 10 pigs, sCR1 (10 mg/kg) was infused 5 minutes after the onset of coronary occlusion (sCR1), 10 received HB-CPB only (HB-CPB), 10 received sCR1 and HB-CPB (sCR1+HB), and 10 received neither sCR1 or HB-CPB (unmodified). Addition of sCR1 to the HB group resulted in less myocardial tissue acidosis (DeltapH = -0.72+/-0.03 for unmodified; -0.46+/-0.05 for HB; -0.18+/-0.04 for sCR1; -0.13+/-0.01 for sCR1+HB), better recovery of wall motion scores (4 = normal to -1 = dyskinesia; 1.67+/-0.17 for unmodified; 2.80+/-0.08 for HB; 3.35+/-0.10 for sCR1; 3.59+/-0.08 for sCR1+HB), less lung water accumulation (5.46+/-0.28% for unmodified; 2.39+/-0.34% for HB; 1.22+/-0.07% for sCR1; 1.24+/-0.13% for sCR1+HB), and smaller infarct size (area necrosis/area risk = 44.6+/-0.7% for unmodified; 33.2+/-1.9% for HB; 19.0+/-2.4% for sCR1; 20+/-1.0% for sCR1+HB) (P<0.05 versus unmodified; P<0.05 versus unmodified and HB groups). CONCLUSIONS Total complement inhibition with sCR1 and sCR1+HB circuits optimizes recovery during the revascularization of ischemic myocardium.

[1]  G. Patterson,et al.  Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine. , 1998, The Journal of thoracic and cardiovascular surgery.

[2]  R. Shemin,et al.  Soluble complement receptor type I limits damage during revascularization of ischemic myocardium. , 1998, The Annals of thoracic surgery.

[3]  B. Nilsson,et al.  Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface. , 1997, Immunopharmacology.

[4]  R. Shemin,et al.  Heparin‐bonded Circuits Improve Clinical Outcomes in Emergency Coronary Artery Bypass Grafting , 1997, Journal of cardiac surgery.

[5]  R. Shemin,et al.  Heparin-bonded circuits decrease myocardial ischemic damage: an experimental study. , 1997, The Annals of thoracic surgery.

[6]  R. Shemin,et al.  Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. , 1996, The Annals of thoracic surgery.

[7]  T. Evans,et al.  Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. , 1996, The Journal of thoracic and cardiovascular surgery.

[8]  P. Bezemer,et al.  Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. , 1995, The Journal of thoracic and cardiovascular surgery.

[9]  L. Greenfield,et al.  Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. , 1994, The Journal of thoracic and cardiovascular surgery.

[10]  G. von Bernuth,et al.  Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. , 1993, The Journal of thoracic and cardiovascular surgery.

[11]  J. H. Jansen,et al.  Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). , 1993, The American journal of pathology.

[12]  J. Halperin,et al.  Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. , 1993, The American journal of physiology.

[13]  W. Baumgartner,et al.  Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[14]  P. Linsley,et al.  Expression and function of B7 on human epidermal Langerhans cells. , 1993, Journal of immunology.

[15]  P. Ward,et al.  Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). , 1992, The Journal of clinical investigation.

[16]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[17]  R. Shemin,et al.  Role of percutaneous bypass in reducing infarct size after revascularization for acute coronary insufficiency. , 1991, Circulation.

[18]  V. Videm,et al.  Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. , 1991, The Journal of thoracic and cardiovascular surgery.

[19]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[20]  M. Entman,et al.  Molecular Basis of Complement Activation in Ischemic Myocardium: Identification of Specific Molecules of Mitochondrial Origin That Bind Human Clq and Fix Complement , 1989, Circulation research.

[21]  M. Gawryl,et al.  Detection of the terminal complement complex in patient plasma following acute myocardial infarction. , 1988, Atherosclerosis.

[22]  S. Bhakdi,et al.  Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. , 1988, The New England journal of medicine.

[23]  E. Fosse,et al.  Complement activation during major operations with or without cardiopulmonary bypass. , 1987, The Journal of thoracic and cardiovascular surgery.

[24]  W. Seeger,et al.  Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. , 1986, Journal of immunology.

[25]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.